Shire Plc American Depositary Shares (SHPG) 213.70 $SHPG
Shire Updates on Pipeline at Research & Development Day - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 11:43AM CST
Shire plc (SHPG) hosted its research and development (R&D) Day and provided key updates on its pipeline.
VRX: 138.71 (-0.18), SHPG: 213.70 (-0.41), SCMP: 13.93 (-0.13), ABBV: 65.27 (-1.76)
PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
M2 - Thu Dec 11, 6:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/tckqjm/pharmapoint) has announced the addition of the "PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update" report to their offering. During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Simponi and Entyvio, which will favor the increased uptake of biologics in the US, 5EU, Japan, and Canada. Although the number of UC prevalent cases is plateauing in the West, globally, the number of cases is rising, a phenomenon that will contribute to market growth over the next decade. Another event affecting the market is the launch of biosimilars, given the patent expiry of the UC blockbusters, Remicade and Humira, in the US in 2018 and 2016, respectively. However, the lack of an established regulatory path for biosimilars in the US presages the slow uptake of these products in this market, which could limit their availability, and consequently, inhibit the growth of the UC market. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively. Overall, major barriers to the growth of the UC market include - Remicade and Humira losing patent protection in the mid-forecast - Austerity measures favoring generic prescribing - Biosimilars are predicted to face low uptake due to the lack of regulatory guidelines in some markets, such as the US Key Findings - The UC market has predominantly been driven by two TNF blockers, namely J&J's Remicade and AbbVie's Humira. Although these TNF blockers have monopolized the UC market for almost a decade, the balance is about to be tipped, with Takeda's Entyvio and J&J's Simponi launch in 2014, stealing market share from Humira and Remicade. - Remicade and Humira will also be hit by their respective loss of patent protection in 2018 (US), 2015 (EU) and 2016 (US), 2018 (EU). Europe has already approved a biosimilar to Remicade, Celltrion's Remsima, which will be marketed by Hospira under the brand name Inflectra in the EU. Due to lack of regulatory guidelines and the current debate about indication extrapolation for biosimilars based on a clinical trial in one indication, initial biosimilar uptake will be low, but by the end of the forecast period, in 2022 infliximab, adalimumab and golimumab biosimilars are forecast to become an established part of the UC market. - During the coming decade, Europe is expecting the approval and launch of a UC colectomy rescue therapy, InDex Pharmaceuticals' Kappaproct. Kappaproct is targeting a small patient population group, but due to the involvement of key gastroenterologists in the development of this therapy, it will likely be welcomed for use in this new treatment setting, which has never been addressed before by a pharmaceutical product. In addition, Pfizer's Xeljanz is expected to face low uptake post its estimated launch in 2017, owing to the controversy surrounding its rejection by the EMA for its primary indication, rheumatoid arthritis. Companies Mentioned - Johnson & Johnson - AbbVie - Takeda Pharmaceuticals - Roche - Warner Chilcott - Salix Pharmaceuticals/Santarus - Shire Pharmaceuticals - Ferring Pharmaceuticals - Pfizer - InDeX Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/tc...harmapoint
JNJ: 104.43 (-2.29), SHPG: 213.70 (-0.41), SLXP: 103.36 (-2.79)
Health Care Stocks: A Year in Review and Predictions for 2015
at The Street - Wed Dec 10, 10:38AM CST
In 2014 drugmakers long on cash but short on growth bought quick access to markets that would have otherwise taken years to build. Can this continue?
ZMH: 111.34 (-1.90), ENDP: 68.77 (-2.45), BDX: 136.99 (-1.03), MDT: 72.52 (-1.25), COV: 100.49 (-1.36), ITMN: 73.89 (-0.02), BMY: 58.75 (-0.93), GSK: 42.42 (-0.93), JNJ: 104.43 (-2.29), CBST: 96.31 (+0.04), CFN: 58.86 (-0.14), SHPG: 213.70 (-0.41), AUXL: 33.11 (-0.72), ABBV: 65.27 (-1.76), IDIX: 24.50 (+0.05), SYK: 92.00 (-1.41), NVS: 93.52 (-0.82)
Notes from Shire's Investor Day: $10B by 2020
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 9:51AM CST
SHPG: 213.70 (-0.41)
Shire R&D Day Profiles Innovative Pipeline Expected to Contribute $3 Billion in Product Sales by 2020
PR Newswire Europe - Wed Dec 10, 6:01AM CST
LEXINGTON, Massachusetts, December 10, 2014 /PRNewswire/ --
SHPG: 213.70 (-0.41)
Cystic Fibrosis Foundation Therapeutics Announces $15 Million Research Collaboration with Shire for Development of Novel CF Treatment
PR Newswire - Wed Dec 10, 5:55AM CST
Cystic Fibrosis Foundation Therapeutics Inc., the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, announced today a $15 million research agreement with Shire plc to support the development of a new cystic fibrosis treatment targeting the underlying cause of the disease.
SHPG: 213.70 (-0.41)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $500,000 From Investment In Shire plc To Contact Brower Piven For More Information
Business Wire - Tue Dec 09, 8:50PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of Illinois on behalf of purchasers of Shire plc ("Shire" or the "Company"
(Nasdaq: SHPG) American Depository Shares or purchased call options or sold put options of Shire between June 20, 2014 and October 14, 2014, inclusive (the "Class Period" .
SHPG: 213.70 (-0.41)
Roof Leaker To Watch: Shire (SHPG)
at The Street - Tue Dec 09, 10:40AM CST
Trade-Ideas LLC identified Shire (SHPG) as a "roof leaker" (crossing below the 200-day simple moving average on higher than normal relative volume) candidate
SHPG: 213.70 (-0.41)
This Could Be the Next Big Pharma Buyout
Motley Fool Staff - Motley Fool - Mon Dec 08, 9:05AM CST
In a bid to offset the risk of patent expiration, drugmakers spend billions of dollars every year on acquisitions to bolster drug pipelines and boost sales. But just because we know that Big Pharma has a penchant for purchases doesn't mean we know...
ZTS: 41.77 (-1.11), MDVN: 106.86 (-1.16), VRX: 138.71 (-0.18), SHPG: 213.70 (-0.41), PFE: 30.95 (-0.70), LLY: 69.55 (-2.06), ABBV: 65.27 (-1.76), BMY: 58.75 (-0.93)
Zacks Industry Outlook Highlights: AbbVie, Shire, Medtronic and Walgreen
PR Newswire - Mon Dec 08, 8:30AM CST
Today, Zacks Equity Research discusses the Medical Tech, including AbbVie Inc. (NYSE:ABBV-Free Report), Shire plc (Nasdaq:SHPG-Free Report), Medtronic Inc. (NYSE:MDT-Free Report) and Walgreen Co. (NYSE:WAG-Free Report).
MDT: 72.52 (-1.25), SHPG: 213.70 (-0.41), ABBV: 65.27 (-1.76)
Cramer's Mad Money - Ulta Salon Is Looking Good (12/5/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Mon Dec 08, 4:43AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday December 5. Ulta Salon (NASDAQ: ULTA ) Is Looking Good Ulta Salon ( ULTA ) was up on Friday, and Cramer recalled a time when it seemed management was...
RH: 93.59 (-0.40), UTX: 112.15 (-1.89), CAH: 79.30 (-1.17), AMGN: 164.53 (-1.55), DIS: 91.49 (-0.26), AZO: 604.73 (+2.34), GILD: 104.13 (-0.18), SHPG: 213.70 (-0.41), COST: 137.88 (-3.53), ABBV: 65.27 (-1.76), AGIO: 119.56 (+0.36), DOV: 67.82 (-2.33), ULTA: 128.67 (-0.77), IDXX: 148.86 (-0.23), LE: 47.60 (+0.77), MBLY: 40.78 (-1.19)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Dec 05, 7:22PM CST
Cramer will be watching for news from Agios Pharmaceuticals and Amgen and awaiting an explanation from United Technologies about its former CEO.
KMI: 39.17 (-0.71), RH: 93.59 (-0.40), UTX: 112.15 (-1.89), CAH: 79.30 (-1.17), HAL: 37.93 (-0.30), AMGN: 164.53 (-1.55), PAA: 47.15 (-1.20), SLB: 80.00 (-3.01), RFMD: 15.50 (-0.29), AZO: 604.73 (+2.34), GILD: 104.13 (-0.18), S: 4.08 (-0.32), SHPG: 213.70 (-0.41), COST: 137.88 (-3.53), ABBV: 65.27 (-1.76), AGIO: 119.56 (+0.36), DOV: 67.82 (-2.33), ULTA: 128.67 (-0.77), IDXX: 148.86 (-0.23), LE: 47.60 (+0.77), CRM: 55.07 (-0.41)
Will MedTech Gain from Republican Promises? - Zacks Analyst Interviews
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 12:00AM CST
Will MedTech Gain from Republican Promises? - Zacks Analyst Interviews
ABT: 43.69 (-0.77), JNJ: 104.43 (-2.29), MDT: 72.52 (-1.25), STE: 65.55 (-0.75), BAX: 71.77 (-1.34), COV: 100.49 (-1.36), SHPG: 213.70 (-0.41), STJ: 66.33 (-0.68), ABBV: 65.27 (-1.76), WAG: 74.50 (+1.49), SYK: 92.00 (-1.41)
Will MedTech Gain from Republican Promises? - Industry Outlook
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 12:00AM CST
Will MedTech Gain from Republican Promises? - Industry Outlook
ABT: 43.69 (-0.77), JNJ: 104.43 (-2.29), MDT: 72.52 (-1.25), STE: 65.55 (-0.75), BAX: 71.77 (-1.34), COV: 100.49 (-1.36), SHPG: 213.70 (-0.41), STJ: 66.33 (-0.68), ABBV: 65.27 (-1.76), WAG: 74.50 (+1.49), SYK: 92.00 (-1.41)
Actavis Launches Generic of Shire's ADHD Drug Intuniv - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 5:45PM CST
Actavis (ACT) launched its generic version of Shire's attention deficit hyperactivity disorder drug Intuniv in the U.S.
AGN: 208.47 (-2.67), ACT: 259.00 (-4.00), AKRX: 41.24 (+0.38), SHPG: 213.70 (-0.41)
Meet 5 Top Drug Stocks That Are Bolting Past Market
at Investor's Business Daily - Tue Dec 02, 7:02AM CST
Celgene and Amgen are among the highly rated companies on IBD's Screen Of The Day, Bolting RS Lines. The Relative Strength line measures how a stock performs compared to the S&P 500 index. RS lines hitting new highs before the actual stock is a...
SHPG: 213.70 (-0.41), AZN: 71.80 (-1.80), AMGN: 164.53 (-1.55), AMAG: 40.04 (-0.79), ABBV: 65.27 (-1.76), HSP: 60.33 (-1.75), CELG: 114.49 (-2.25)
Dimension Therapeutics Expands Leadership Team, Names Eric Crombez, M.D., as Chief Medical Officer
Business Wire - Tue Dec 02, 6:30AM CST
--- Dimension Advancing Proprietary Gene Therapy Programs toward Clinical Testing; First Trial Expected to Commence in Hemophilia B Patients in 2015 -
SHPG: 213.70 (-0.41)
Novartis' Cardiovascular Drug Gets Accelerated Assessment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 01, 4:40PM CST
Positive news flowed in for Novartis (NVS) when it announced that the Committee for Medicinal Products for Human Use (CHMP) has granted accelerated assessment to its pipeline candidate LCZ696.
AGN: 208.47 (-2.67), SHPG: 213.70 (-0.41), ABBV: 65.27 (-1.76), NVS: 93.52 (-0.82)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $500,000 From Investment in Shire plc to Contact Brower Piven for More Information -- SHPG
GlobeNewswire - Mon Dec 01, 3:42PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of Illinois on behalf of purchasers of Shire plc ("Shire" or the "Company" (Nasdaq:SHPG) American Depository Shares or purchased call options or sold put options of Shire between June 20, 2014 and October 14, 2014, inclusive (the "Class Period" .
SHPG: 213.70 (-0.41)
Shire Updates on Pipeline at Research & Development Day - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 11:43AM CST
Shire plc (SHPG) hosted its research and development (R&D) Day and provided key updates on its pipeline.
VRX: 138.71 (-0.18), SHPG: 213.70 (-0.41), SCMP: 13.93 (-0.13), ABBV: 65.27 (-1.76)
PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
M2 - Thu Dec 11, 6:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/tckqjm/pharmapoint) has announced the addition of the "PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update" report to their offering. During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Simponi and Entyvio, which will favor the increased uptake of biologics in the US, 5EU, Japan, and Canada. Although the number of UC prevalent cases is plateauing in the West, globally, the number of cases is rising, a phenomenon that will contribute to market growth over the next decade. Another event affecting the market is the launch of biosimilars, given the patent expiry of the UC blockbusters, Remicade and Humira, in the US in 2018 and 2016, respectively. However, the lack of an established regulatory path for biosimilars in the US presages the slow uptake of these products in this market, which could limit their availability, and consequently, inhibit the growth of the UC market. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively. Overall, major barriers to the growth of the UC market include - Remicade and Humira losing patent protection in the mid-forecast - Austerity measures favoring generic prescribing - Biosimilars are predicted to face low uptake due to the lack of regulatory guidelines in some markets, such as the US Key Findings - The UC market has predominantly been driven by two TNF blockers, namely J&J's Remicade and AbbVie's Humira. Although these TNF blockers have monopolized the UC market for almost a decade, the balance is about to be tipped, with Takeda's Entyvio and J&J's Simponi launch in 2014, stealing market share from Humira and Remicade. - Remicade and Humira will also be hit by their respective loss of patent protection in 2018 (US), 2015 (EU) and 2016 (US), 2018 (EU). Europe has already approved a biosimilar to Remicade, Celltrion's Remsima, which will be marketed by Hospira under the brand name Inflectra in the EU. Due to lack of regulatory guidelines and the current debate about indication extrapolation for biosimilars based on a clinical trial in one indication, initial biosimilar uptake will be low, but by the end of the forecast period, in 2022 infliximab, adalimumab and golimumab biosimilars are forecast to become an established part of the UC market. - During the coming decade, Europe is expecting the approval and launch of a UC colectomy rescue therapy, InDex Pharmaceuticals' Kappaproct. Kappaproct is targeting a small patient population group, but due to the involvement of key gastroenterologists in the development of this therapy, it will likely be welcomed for use in this new treatment setting, which has never been addressed before by a pharmaceutical product. In addition, Pfizer's Xeljanz is expected to face low uptake post its estimated launch in 2017, owing to the controversy surrounding its rejection by the EMA for its primary indication, rheumatoid arthritis. Companies Mentioned - Johnson & Johnson - AbbVie - Takeda Pharmaceuticals - Roche - Warner Chilcott - Salix Pharmaceuticals/Santarus - Shire Pharmaceuticals - Ferring Pharmaceuticals - Pfizer - InDeX Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/tc...harmapoint
JNJ: 104.43 (-2.29), SHPG: 213.70 (-0.41), SLXP: 103.36 (-2.79)
Health Care Stocks: A Year in Review and Predictions for 2015
at The Street - Wed Dec 10, 10:38AM CST
In 2014 drugmakers long on cash but short on growth bought quick access to markets that would have otherwise taken years to build. Can this continue?
ZMH: 111.34 (-1.90), ENDP: 68.77 (-2.45), BDX: 136.99 (-1.03), MDT: 72.52 (-1.25), COV: 100.49 (-1.36), ITMN: 73.89 (-0.02), BMY: 58.75 (-0.93), GSK: 42.42 (-0.93), JNJ: 104.43 (-2.29), CBST: 96.31 (+0.04), CFN: 58.86 (-0.14), SHPG: 213.70 (-0.41), AUXL: 33.11 (-0.72), ABBV: 65.27 (-1.76), IDIX: 24.50 (+0.05), SYK: 92.00 (-1.41), NVS: 93.52 (-0.82)
Notes from Shire's Investor Day: $10B by 2020
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 9:51AM CST
SHPG: 213.70 (-0.41)
Shire R&D Day Profiles Innovative Pipeline Expected to Contribute $3 Billion in Product Sales by 2020
PR Newswire Europe - Wed Dec 10, 6:01AM CST
LEXINGTON, Massachusetts, December 10, 2014 /PRNewswire/ --
SHPG: 213.70 (-0.41)
Cystic Fibrosis Foundation Therapeutics Announces $15 Million Research Collaboration with Shire for Development of Novel CF Treatment
PR Newswire - Wed Dec 10, 5:55AM CST
Cystic Fibrosis Foundation Therapeutics Inc., the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, announced today a $15 million research agreement with Shire plc to support the development of a new cystic fibrosis treatment targeting the underlying cause of the disease.
SHPG: 213.70 (-0.41)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $500,000 From Investment In Shire plc To Contact Brower Piven For More Information
Business Wire - Tue Dec 09, 8:50PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of Illinois on behalf of purchasers of Shire plc ("Shire" or the "Company"
(Nasdaq: SHPG) American Depository Shares or purchased call options or sold put options of Shire between June 20, 2014 and October 14, 2014, inclusive (the "Class Period" . SHPG: 213.70 (-0.41)
Roof Leaker To Watch: Shire (SHPG)
at The Street - Tue Dec 09, 10:40AM CST
Trade-Ideas LLC identified Shire (SHPG) as a "roof leaker" (crossing below the 200-day simple moving average on higher than normal relative volume) candidate
SHPG: 213.70 (-0.41)
This Could Be the Next Big Pharma Buyout
Motley Fool Staff - Motley Fool - Mon Dec 08, 9:05AM CST
In a bid to offset the risk of patent expiration, drugmakers spend billions of dollars every year on acquisitions to bolster drug pipelines and boost sales. But just because we know that Big Pharma has a penchant for purchases doesn't mean we know...
ZTS: 41.77 (-1.11), MDVN: 106.86 (-1.16), VRX: 138.71 (-0.18), SHPG: 213.70 (-0.41), PFE: 30.95 (-0.70), LLY: 69.55 (-2.06), ABBV: 65.27 (-1.76), BMY: 58.75 (-0.93)
Zacks Industry Outlook Highlights: AbbVie, Shire, Medtronic and Walgreen
PR Newswire - Mon Dec 08, 8:30AM CST
Today, Zacks Equity Research discusses the Medical Tech, including AbbVie Inc. (NYSE:ABBV-Free Report), Shire plc (Nasdaq:SHPG-Free Report), Medtronic Inc. (NYSE:MDT-Free Report) and Walgreen Co. (NYSE:WAG-Free Report).
MDT: 72.52 (-1.25), SHPG: 213.70 (-0.41), ABBV: 65.27 (-1.76)
Cramer's Mad Money - Ulta Salon Is Looking Good (12/5/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Mon Dec 08, 4:43AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday December 5. Ulta Salon (NASDAQ: ULTA ) Is Looking Good Ulta Salon ( ULTA ) was up on Friday, and Cramer recalled a time when it seemed management was...
RH: 93.59 (-0.40), UTX: 112.15 (-1.89), CAH: 79.30 (-1.17), AMGN: 164.53 (-1.55), DIS: 91.49 (-0.26), AZO: 604.73 (+2.34), GILD: 104.13 (-0.18), SHPG: 213.70 (-0.41), COST: 137.88 (-3.53), ABBV: 65.27 (-1.76), AGIO: 119.56 (+0.36), DOV: 67.82 (-2.33), ULTA: 128.67 (-0.77), IDXX: 148.86 (-0.23), LE: 47.60 (+0.77), MBLY: 40.78 (-1.19)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Dec 05, 7:22PM CST
Cramer will be watching for news from Agios Pharmaceuticals and Amgen and awaiting an explanation from United Technologies about its former CEO.
KMI: 39.17 (-0.71), RH: 93.59 (-0.40), UTX: 112.15 (-1.89), CAH: 79.30 (-1.17), HAL: 37.93 (-0.30), AMGN: 164.53 (-1.55), PAA: 47.15 (-1.20), SLB: 80.00 (-3.01), RFMD: 15.50 (-0.29), AZO: 604.73 (+2.34), GILD: 104.13 (-0.18), S: 4.08 (-0.32), SHPG: 213.70 (-0.41), COST: 137.88 (-3.53), ABBV: 65.27 (-1.76), AGIO: 119.56 (+0.36), DOV: 67.82 (-2.33), ULTA: 128.67 (-0.77), IDXX: 148.86 (-0.23), LE: 47.60 (+0.77), CRM: 55.07 (-0.41)
Will MedTech Gain from Republican Promises? - Zacks Analyst Interviews
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 12:00AM CST
Will MedTech Gain from Republican Promises? - Zacks Analyst Interviews
ABT: 43.69 (-0.77), JNJ: 104.43 (-2.29), MDT: 72.52 (-1.25), STE: 65.55 (-0.75), BAX: 71.77 (-1.34), COV: 100.49 (-1.36), SHPG: 213.70 (-0.41), STJ: 66.33 (-0.68), ABBV: 65.27 (-1.76), WAG: 74.50 (+1.49), SYK: 92.00 (-1.41)
Will MedTech Gain from Republican Promises? - Industry Outlook
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 12:00AM CST
Will MedTech Gain from Republican Promises? - Industry Outlook
ABT: 43.69 (-0.77), JNJ: 104.43 (-2.29), MDT: 72.52 (-1.25), STE: 65.55 (-0.75), BAX: 71.77 (-1.34), COV: 100.49 (-1.36), SHPG: 213.70 (-0.41), STJ: 66.33 (-0.68), ABBV: 65.27 (-1.76), WAG: 74.50 (+1.49), SYK: 92.00 (-1.41)
Actavis Launches Generic of Shire's ADHD Drug Intuniv - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 5:45PM CST
Actavis (ACT) launched its generic version of Shire's attention deficit hyperactivity disorder drug Intuniv in the U.S.
AGN: 208.47 (-2.67), ACT: 259.00 (-4.00), AKRX: 41.24 (+0.38), SHPG: 213.70 (-0.41)
Meet 5 Top Drug Stocks That Are Bolting Past Market
at Investor's Business Daily - Tue Dec 02, 7:02AM CST
Celgene and Amgen are among the highly rated companies on IBD's Screen Of The Day, Bolting RS Lines. The Relative Strength line measures how a stock performs compared to the S&P 500 index. RS lines hitting new highs before the actual stock is a...
SHPG: 213.70 (-0.41), AZN: 71.80 (-1.80), AMGN: 164.53 (-1.55), AMAG: 40.04 (-0.79), ABBV: 65.27 (-1.76), HSP: 60.33 (-1.75), CELG: 114.49 (-2.25)
Dimension Therapeutics Expands Leadership Team, Names Eric Crombez, M.D., as Chief Medical Officer
Business Wire - Tue Dec 02, 6:30AM CST
--- Dimension Advancing Proprietary Gene Therapy Programs toward Clinical Testing; First Trial Expected to Commence in Hemophilia B Patients in 2015 -
SHPG: 213.70 (-0.41)
Novartis' Cardiovascular Drug Gets Accelerated Assessment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 01, 4:40PM CST
Positive news flowed in for Novartis (NVS) when it announced that the Committee for Medicinal Products for Human Use (CHMP) has granted accelerated assessment to its pipeline candidate LCZ696.
AGN: 208.47 (-2.67), SHPG: 213.70 (-0.41), ABBV: 65.27 (-1.76), NVS: 93.52 (-0.82)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $500,000 From Investment in Shire plc to Contact Brower Piven for More Information -- SHPG
GlobeNewswire - Mon Dec 01, 3:42PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of Illinois on behalf of purchasers of Shire plc ("Shire" or the "Company"
(Nasdaq:SHPG) American Depository Shares or purchased call options or sold put options of Shire between June 20, 2014 and October 14, 2014, inclusive (the "Class Period" . SHPG: 213.70 (-0.41)
